Research programme: embryonic stem cell therapies - Stem Cell and Regenerative Medicine International

Drug Profile

Research programme: embryonic stem cell therapies - Stem Cell and Regenerative Medicine International

Alternative Names: Hemangioblast cell programme - Astellas

Latest Information Update: 21 Apr 2016

Price : $50

At a glance

  • Originator Advanced Cell Technology
  • Developer Advanced Cell Technology; Astellas Pharma; Stem Cell & Regenerative Medicine International
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders
  • No development reported Wounds

Most Recent Events

  • 14 Nov 2014 Advanced Cell Technology is now called Ocata Therapeutics
  • 07 Apr 2014 Preclinical development is ongoing in USA
  • 21 Jul 2011 Haemangioblast programme licensed to Advanced Cell Technology in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top